Home / Letter From The Editor / Editor’s Note

Editor’s Note

Jan 18, 2018

I remember when I got the call to be on an advisory board for the first SGLT-2 inhibitor. The science made sense but it seemed that everyone was worried about the “tremendous” risk of UTI’s due to excess urination and glucose in the urine. I think this came from a general misunderstanding of what the drug did.

When I would recommend these products to prescribers I worked with, most had no idea that they worked to fix a defect. As they gained experience with the class, they realized that the fear of UTI’s was generally overrated. They were also impressed by their patients’ experience with decreased blood pressure values and weight loss.

Over the past 4 years, further research has pointed to the cardio-protective nature of the class and how well these medications work with other treatments. This week as we begin the New Year we are happy to bring you our first special issue on SGLT-2 Inhibitors, by sharing therapy choice information.


We can make a difference!


Dave Joffe